TECN1N Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage gives Tecan financial flexibility to fund product development, transformation initiatives and customer support without excessive balance-sheet strain, helping it navigate cyclical laboratory-equipment demand and temporary earnings pressure.
Resilient Cash GenerationPersistent positive operating and free cash flow indicates that Tecan’s installed-base, service and consumables economics continue to support internal funding. This provides resilience despite weaker reported earnings, although recent cash momentum requires monitoring.
Growth And Transformation PotentialReiterated guidance, above-market segment growth and early Rewired savings provide a credible pathway to improved scale and profitability. The program, AI initiatives and geographic expansion could strengthen competitiveness if execution converts targets into durable gains.
Bears Say
Multi-Year Revenue Decline And 2025 LossThree consecutive years of revenue contraction indicate sustained demand or execution challenges rather than a single-quarter setback. The 2025 swing to a substantial net loss weakens earnings quality and increases reliance on a successful operational recovery.
Margin CompressionLower gross and operating margins show that inflation, inventory effects, FX and tariffs are absorbing operating leverage. Persistent cost pressure could limit the benefit of sales growth and make the 2028 margin ambition dependent on successful restructuring.
Execution, Cash And Supply-Chain RiskWorking-capital absorption, weaker liquidity and delayed Cavro shipments create execution risk while Tecan is funding Rewired and Elevate. These pressures can defer revenue recognition, constrain cash conversion and increase the cost of achieving transformation targets.
Tecan Group AG News
TECN1N FAQ
What was Tecan Group AG’s price range in the past 12 months?
Currently, no data Available
What is Tecan Group AG’s market cap?
Tecan Group AG’s market cap is $52.18B.
When is Tecan Group AG’s upcoming earnings report date?
Tecan Group AG’s upcoming earnings report date is Mar 16, 2027 which is in 201 days.
How were Tecan Group AG’s earnings last quarter?
Tecan Group AG released its earnings results on Aug 11, 2026. The company reported $55.514 earnings per share for the quarter, beating the consensus estimate of $53.184 by $2.331.
Is Tecan Group AG overvalued?
According to Wall Street analysts Tecan Group AG’s price is currently Undervalued.
Does Tecan Group AG pay dividends?
Tecan Group AG does not currently pay dividends.
What is Tecan Group AG’s EPS estimate?
Tecan Group AG’s EPS estimate is 82.85.
How many shares outstanding does Tecan Group AG have?
Tecan Group AG has 12,825,883 shares outstanding.
What happened to Tecan Group AG’s price movement after its last earnings report?
Tecan Group AG reported an EPS of $55.514 in its last earnings report, beating expectations of $53.184. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Tecan Group AG?
Currently, no hedge funds are holding shares in MX:TECN1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tecan Group AG
Tecan Group AG, established in 1980 and headquartered in Männedorf, Switzerland, specializes in providing cutting-edge laboratory instruments and holistic solutions. The company caters to a broad spectrum of clients, including pharmaceutical and biotechnology corporations, university research departments, and forensic and diagnostic laboratories. Its operations are structured into two principal segments: Life Sciences Business and Partnering Business. Tecan's extensive product portfolio features automated liquid handling systems, microplate readers and washers, various consumables, reagents for Next-Generation Sequencing (NGS), immunoassays, microbodies, and specialized software. Key proprietary solutions include Tecan Laberwax for automated workflows and Resolvex, an intelligent sample preparation system applicable across diverse fields such as genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA. Additionally, Tecan develops and manufactures crucial components—like precision pumps, valves, robotic arms, and developer software—for other laboratory instrument producers serving life science research, diagnostics, and various industrial applications. Its advanced platform-based automation solutions include Synergence, Freedom EVO, and Fluent instruments. The company's global footprint spans Switzerland, other European nations, North America, Asia, and other international markets.
TECN1N Company Deck
TECN1N Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call painted an overall constructive picture: Tecan delivered above-market sales growth in local currencies, maintained a healthy book-to-bill and recorded a resilient adjusted EBITDA margin with underlying profitability improvement. Management confirmed multi-year targets and reported early, tangible benefits from the Rewired transformation alongside strategic AI and geographic initiatives. However, material challenges remain — gross margin compression (material inflation, FX and tariffs), weaker operating cash flow, supply-chain shipment delays (Cavro), upfront transformation and IT costs, and weakness in the Academia & Government end market. On balance, the positive operational momentum, validated guidance and strategic progress outweigh the near-term financial and operational headwinds, but the company must execute Rewired and Elevate while stabilizing cash conversion and margins.View all MX:TECN1N earnings summaries